In cancer of the liver, lung, prostate, ovary, and breast, among others, there are antecedents that the reduction or silencing of one or more SOCS correlates with tumor progression and poor overall survival [155,156,157,158,159]. The gene discussed is CISH; the disease is neoplasm.